Background: T-cell responses against dormancy-, resuscitation-, and reactivation-associated antigens of Mycobacterium tuberculosis are candidate biomarkers of latent infection in humans.
Introduction
In the vast majority of individuals, specific cellular immunity against M. tuberculosis is capable of controlling infection leading to latent M. tuberculosis infection (LTBI) [1] . LTBI is thought to be associated with a dormancy/non-replicating state of low metabolic activity of the pathogen. Dormancy-related (DosR) antigens as well as proteins expressed during reactivation and resuscitation of dormant bacilli are candidate biomarkers for LTBI and disease reactivation [2, 3, 4] . A limited number of studies tested latencyassociated antigens in immunologic assays. These showed that DosR antigens induced T-cell cytokine expression in humans [5] and mice [6] . Resuscitation-promoting factors (rpf) induced immune responses in mice [7] but have not been tested in humans. Recent studies based on M. tuberculosis knock-out strains revealed that Rv3407, a protein which is not expressed in M. bovis BCG at detectable abundance [8] , is under the control of two rpf [9] . Neither Rv3407 nor reactivation-associated antigens (i.e. Rv0104, Rv1115 [10] ) have been tested for immunogenicity so far. For reasons of comprehensibility we use the term latencyassociated antigens for M. tuberculosis proteins involved in dormancy, resuscitation, and reactivation of M. tuberculosis.
We tested the immunogenicity of 35 latency-associated antigens using different assays based on intracellular cytokine staining for IFNc and IFNc-ELISA. IFNc is a crucial mediator of protection against tuberculosis which strongly depends on T helper type-1 immunity. IFNc activates infected macrophages at the site of bacterial residence -an essential mechanism for the killing of mycobacteria [11] . IFNc release in response to immunodominant antigens (i.e. ESAT6, CFP10) is used in standard tests for M. tuberculosis infection (IFNc release assays, IGRA) [12] .
IGRA as well as standard intracellular cytokine staining methods are based on short-term incubation between 6 and 24 h [13] . Principally short-term assays detect recent M. tuberculosis infection while prolonged in vitro stimulation increases sensitivity for LTBI [14, 15, 16 ]. Yet, these assays remain insufficient as robust correlates of protection against M. tuberculosis [17] . Therefore, biomarkers which reliably predict protective immunity are urgently needed [18] . Antigens predominantly expressed by dormant M. tuberculosis during LTBI are promising candidate immune markers of protection [5] . We therefore decided to develop an assay based on two rounds of in vitro restimulation, to determine IFNc production in response to M. tuberculosis latencyassociated antigens in LTBI, TB patients, and tuberculin skin test (TST)-negative donors. Differentially expressed proteins were then tested for their capacity to discriminate between LTBI and TB patients. Finally, overlapping peptide pools were applied to identify immunogenic epitopes of the most promising candidate, Rv3407.
Results

Two-rounds of in vitro restimulation detect T-cell responses against latency-associated antigens
We assessed 29 antigens associated with M. tuberculosis dormancy, resuscitation, and reactivation (in short latency, Table 1 ) for their potential to elicit recall responses after 16 h short-term in vitro stimulation of PBMC from LTBI. We detected IFNc expression in CD4 + CD45RO + memory T cells from LTBI after stimulation with PPD from M. tuberculosis and, to a minor degree, with M. tuberculosis-immunodominant proteins ESAT6_CFP-10, TB10.4, and Ag85a ( figure 1A) . Notably, none of the latency-associated antigens induced detectable cytokine expression after 16 h in LTBI ( figure 1A ) and no T-cell responses against M. tuberculosis-specific antigens were detected in 10 tuberculin skin test (TST)-negative donors (data not shown).
Increased T cell-derived IFNc responses after prolonged in vitro incubation have been described [5, 14, 16] . Since our own previous experiments indicated that a second stimulation before measurement with the same antigen is optimal for intracellular cytokine detection (data not shown), we combined 7 days of stimulation with restimulation 16 h prior to analysis. Frequencies of IFNcexpressing T cells in PBMC from LTBI were markedly increased after stimulation with immunodominant proteins or PPD for 7 days ( figure 1B, upper graph) . In contrast to the short-term single stimulation assay, latency-associated antigens induced IFNc expression in memory T cells from the majority of LTBI in the long-term restimulation assay ( figure 1B, upper graph) . Two of these latency-associated antigens, namely Rv0569 and Rv3407, induced IFNc expression comparable to the ESAT6_CFP-10 fusion protein, the immunodominant antigen which induced the highest frequencies of cytokine-expressing cells in LTBI. In contrast, none of the antigens induced detectable IFNc expression in T cells from TST-negative donors in this assay (figure 1B, lower graph). Hence, the ''7-day two rounds of restimulation'' assay detects specific T-cell responses in LTBI which are missed by the 16h short-term assay.
Comparisons for the individual donor T-cell responses after 7 days and two rounds of restimulation revealed comparable results against three selected immunodominant antigens (i.e. ESAT6_CFP-10, TB10.4, Ag85A) and three latency-associated antigens (i.e. Rv0569, Rv1734, Rv2003) (data not shown). Considering significantly higher proportions of T cells specific for immunodominant antigens in the short-term assay, a simply 'boosted' T-cell response by prolonged stimulation would not explain equal proportions since this would have led to higher proportions of T cells specific for immunodominant antigens in the 7-day assay.
Analyses of IFNc in supernatants by ELISA at day 7 following two rounds of restimulation revealed a similar tendency for PPD, immunodominant, and latency-associated M. tuberculosis proteins in LTBI (figure 2A). In contrast to intracellular staining, a considerable amount of IFNc was also detected in supernatants of PBMC from some TST-negative donors after stimulation with latency-associated antigens (figure 2B). Therefore intracellular measurement of IFNc after two rounds of in vitro restimulation revealed higher specificity as compared to the IFNc ELISA.
Significantly stronger T-cell responses in LTBI as compared to TB patients against latency-associated antigens
The expression of the vast majority of antigens used in this study has been associated with latent stages of M. tuberculosis infection. Consequently, we addressed the question whether these antigens are differentially recognized by T cells from patients with active pulmonary TB and LTBI. Eleven latency-associated antigens (i.e. Rv0569, Rv1733c, Rv1734, Rv2003, Rv2005c, Rv2006, Rv0140, Rv1009, Rv1884c, Rv2450c, and Rv3407), which induced strong responses in LTBI, were selected for these experiments. Seven of these latency-associated antigens induced significantly higher Tcell responses in LTBI as compared to TB patients (P,0.001 for Rv1733c, Rv2003, Rv2005c, Rv0140, and Rv3407; P,0.01 for Rv1009; P,0.05 for Rv2450c) ( figure 3A ).
We set a threshold of 0.2% IFNc + , CD4 + , CD45RO + T cells (i.e. 20-fold above the assumed flow cytometric detection threshold of 0.01%) to define positive T-cell responses against latencyassociated antigens in LTBI and TB patients for the most promising candidates (P,0.001) ( Table 2 ). Latency-associated antigens induced T-cell responses in the range of 45.5 to 72.7% of LTBI patients. A specific T-cell response against Rv2003 was detected in the vast majority of LTBI (16 of 22) but also induced T-cell responses against latency-associated antigens discriminate between LTBI and TB patients
We included the 11 immunogenic latency-associated antigens together with ESAT6_CFP-10, and PPD in a discrimination approach. Random forest analyses together with leave-1-out cross-validations across all possible combinations were applied to determine the prediction accuracy and relative importance of each factor for classification. These analyses revealed a crossvalidated prediction accuracy of 83% between TB patients and LTBI (figure 3B). The relative feature importance for discrimination showed that Rv3407 was by far the most influential factor for classification ( figure 3C ). Consequently we designed overlapping peptide pools of Rv3407 to identify immunogenic epitopes.
Identification of immunogenic peptides of Rv3407
The matrix design of the overlapping peptide pools leads to six 'vertical' and five 'horizontal' pools. Each of the 29 peptides of Rv3407 was present in two pools (Table 3 ). In 6 out of 10 LTBI tested -those with the highest T-cell response against Rv3407 -a minimum of 0.2% IFNc-expressing CD4 + T cells was detected after stimulation with at least two of the peptide pools (figure 4). In four LTBI (LTBI-A to LTBI-D) a major immunogenic epitope could be identified (figure 4A-D) while in two LTBI (LTBI-E, LTBI-F) with the weakest response against the Rv3407 protein no prominent epitope-specific T-cell responses were observed (figure 4E-F). Notably peptide 6 (LRQHASRYLARVEAG) identified in LTBI-A induced IFNc expression in about 1% of CD8 + memory T cells, as well (data not shown). Therefore distinct peptide epitopes in different LTBI were recognized by antigenspecific T cells and ongoing studies will determine whether this is due to differential HLA-phenotypes.
We consider the detection of specific T-cell immunity against latency-associated antigens and the identification of immunogenic epitopes an initial step towards definition of reliable biomarkers for protective immunity against TB. Discussion T-cell immunity in LTBI is crucial for protection against resuscitation and reactivation of M. tuberculosis. We established two rounds of in vitro restimulation assay that induced specific T-cell immunity against latency-associated antigens which were not detected in a short-term T-cell assay. These intracellular IFNc responses were significantly increased in LTBI as compared to TB patients. This assay was highly specific since IFNc-expressing memory T cells were only detected in PBMC from LTBI and not from TST-negative donors.
We identified a subgroup of latency-associated antigens that induced significantly stronger T-cell responses in LTBI as compared to TB patients. This is in accordance with a previous study that showed increased responses against the latency- associated antigen Rv1733c in LTBI as compared to TB patients [5] . The remaining candidates (i.e. DosR regulon-encoded proteins Rv2003 and Rv2005c, the reactivation-associated protein Rv0140, the resuscitation promoting factors Rv2450c and Rv1009, as well as Rv3407) have not been tested so far. Rv3407 induced IFNc in T cells exclusively of LTBI. We identified Rv3407 previously by comparative proteomics of M. tuberculosis strain H37Rv and M. bovis BCG [8, 19] . Rv3407 improved the vaccine efficacy of BCG suggesting that subunit vaccination can be used to improve pre-existing protection evoked by BCG [19] . Ongoing studies in our institute aim at characterizing the biological and antigenic role of Rv3407. Furthermore all immunogenic protein candidates identified in this study will be analyzed for the induction of protective T-cell responses in TB high-incidence countries (www.biomarkers-for-tb.net). T-cell responses against this subgroup of latency-associated antigens classified LTBI and TB patients with an accuracy of 83% and Rv3407 contributed significantly to discrimination. The discrimination efficacy was comparable to studies of blood cell counts and ex vivo serum cytokine analyses in fast and slow treatment responders [20] and was only slightly lower than RNAbased candidate markers in PBMC from TB patients and LTBI [21] or a serum-based proteomic approach [22] .
We determined IFNc expression in T cells specific for latencyassociated antigens. TNFa-expression revealed comparable results and a strongly overlapping cytokine expression pattern (data not shown) while IL-2 expression was not detectable after 7 days of in vitro restimulation (data not shown). Therefore T cells induced by latency-associated antigens show a phenotype of multifunctional T cells, which have been shown to protect against TB in the mouse model [23] . We have shown recently that GM-CSF expressing multifunctional T cells are not increased in TB patients while other cytokines were increased in TB patients as compared to LTBI [24] . Ongoing longitudinal prospective studies analyze whether the frequency and phenotype of latency antigen-specific T cells in LTBI is associated with the risk of developing TB at a later time point and hence can be exploited for prognostic diagnosis (www.biomarkers-for-tb.net). One important aspect that will be addressed in these studies is the lack of T cells specific for latencyassociated antigens in active TB patients although it is likely that most TB patients undergo a phase of latent infection prior to active disease. As an initial attempt to address this point we determined T-cell responses twice (prior to and under drug treatment) for a subgroup of TB patients (data not shown) and detected increased frequencies for some of the latency proteins in patients under drug treatment. Therefore the lack of latencyassociated T cells at least for some antigens seems to be restricted to the acute TB phase. This could be explained i) by the recruitment of these T cells to the lung or ii) increased T-cell regulation during the acute TB phase.
In contrast to intracellular IFNc analyses, some IFNc was also detected in supernatants of PBMC from a subgroup of TSTnegative donors after stimulation with latency-associated antigens as described previously [5] . The second round of restimulation did not cause this higher background in TST-negative donors, since supernatants collected at day 6 from a subgroup of uninfected donors showed similar IFNc abundance as compared to the day 7 time point after restimulation (data not shown). Using flow cytometry, we excluded the possibility that other immune cell populations (e.g. NK cells, NKT cells, CD8 + T cells) were the source of IFNc (data not shown). A possible explanation would be exhaustion or induced cell death (e.g. by apoptosis) after restimulation 16 h prior to analysis [25] . Alternatively, these donors could be false negative in the T-Spot TBß although we have no evidence to support this assumption, or these responses reflect cross-reactivity towards antigens expressed by commensal bacteria [26] .
In an initial attempt to characterize the T-cell responses against latency-associated antigens we compared the T-cell responses against immunodominant and latency-associated antigens from individual donors. While immunodominant antigens ESAT6_CFP-10, TB10.4, Ag85a induced significantly stronger T-cell responses in the 16-h short-term assay as compared to latency-associated antigens (i.e. Rv0569, Rv1734, Rv2003), comparable proportions of IFNc-producing T cells were detected in the 7-day two rounds of restimulation assay. We conclude that a simply 'boosted' T-cell response by prolonged stimulation and two rounds of restimulation did not cause this effect as this would lead to higher proportions of T cells specific for immunodominant antigens. Distinct maturation stage of T-cell populations specific for latency-associated antigens may account for these findings. This may lead to differences in the activation threshold prerequisite for in vitro cytokine expression. Previous studies demonstrated higher sensitivity of a 6-day whole blood assay for T-cell responses in LTBI suggesting that prolonged in vitro restimulation preferentially induced central memory T cells [14, 16] . This supports the notion that T cells specific for latency-associated antigen have a distinct maturation/activation status. Detailed investigation of both T-cell populations will be performed in the future, including global gene expression profiling.
Materials and Methods
Ethics Statement
The clinical investigations have been conducted according to the principles expressed in the Declaration of Helsinki. All donors gave written informed consent and the local ethics committee of 
Human subjects
Peripheral blood (40 ml) was obtained from 22 LTBI and 20 patients with active pulmonary TB. LTBI and TB patients were recruited at HELIOS clinic Emil-von-Behring and the Charité, both in Berlin; and at the Asklepios Clinic, Munich-Gauting. Diagnosis of LTBI was based on positive TST (.10 mm) and positive T-Spot TB TM . TB diagnosis was based on patient history, chest X-ray, TST, and mycobacterial culture. Ten M. tuberculosis non-infected (TST-negative) donors were recruited among volunteers of the Max Planck Institute for Infection Biology, Berlin. All donors were Caucasians. There was no gender bias and only minor age differences between both study groups (Table 4) .
Recombinant M. tuberculosis proteins and synthetic peptide pools
Recombinant M. tuberculosis proteins (Table 1) were expressed in Escherichia coli and purified as described previously [5, 27] . Synthetic 15-mer peptide pools representing Rv3407 were generated with an overlap of 12 amino acids using combinatory chemistry (Jerini). The pools were designed as matrix pools as described before [28] . The peptides are listed in Table 3 .
Cell culture assays
Peripheral blood mononuclear cells (PBMC) were isolated by density centrifugation (Biocoll, Biochrom) following manufactur- er's instructions and 2610 5 cells were cultured in 200 mL medium A [(RPMI-1640 (GIBCO, Invitrogen) with 10% human serum (Sigma-Aldrich), 100 U/ml penicillin, 100 mg/ml streptomycin, 1 mM L-glutamine and 10 mM HEPES (all PAA laboratories)] using 96-well round-bottom plates (NUNC). Each well was surrounded by wells filled with sterile water (200 ml) to avoid drying effects. In the short-term assay we stimulated PBMC for 16 h with different recombinant M. tuberculosis proteins (5 mg/ml, see Table 1 ), purified protein derivative (PPD) of M. tuberculosis (5 mg/ml) (Statens Serum Institute), Staphylococcus enterotoxin B (SEB) (1 mg/ml) (Sigma-Aldrich), and synthetic peptide pools (5 mg/ml per peptide) at 37uC and 5% CO 2 . After 4 h of incubation brefeldin A (10 mg/ml) (Sigma-Aldrich) was added.
In the long-term assay the same stimuli were applied at the beginning except for SEB that was added on day 6 to a well of non-stimulated cultured cells. For each of the other stimuli the same antigen was added on day 6 in 20 ml medium A using the same final concentrations. In the long-term assay, brefeldin A (10 mg/ml) was added 4 h after the second restimulation only, and cells were then cultured for an additional 12 h.
Afterwards, for both assays, cells were fixed and permeabilized using cytofix/cytoperm TM (BD Biosciences) following manufacturer's instructions and stained with the following fluorochromelabeled monoclonal antibodies: a-CD3 (Pacific Blue) (BioLegend), a-CD4 (APC-Cy7), a-CD8 (PerCP), a-CD45RO (Pe-Cy7), a-IFNc (APC) (all BD Biosciences). After staining for 45 min at 4uC, cells were washed twice in cytoperm/wash, and once in PBS containing 10% FCS. Measurements and analyses were performed using a LSRII flow cytometer and FACS-Diva software (both BD Biosciences). Examples of the procedures of analysis are shown in Figure 5A for a TB patient and Figure 5B for an LTBI. About 18000 CD4
+ CD45RO + T cells were collected for each sample. For background determinations, values of non-stimulated controls were subtracted from the different stimuli of each individual donor.
Cytokine analyses in culture supernatants by ELISA PBMC (5610 4 ) were added to 96-well round-bottom plates (NUNC) in 200 mL medium. Cells were stimulated for 7 days as described in the previous section but without adding brefeldin A. We harvested 110 ml of cell culture supernatant at day 7. The IFNc ELISA (BD Biosciences) was performed according to manufacturer's guidelines. Plates were analyzed by measuring extinction at 450 nm using an ELISA plate reader (Molecular Devices).
Donor classification and significance analyses
The discriminatory power for classifying TB patients and LTBI was investigated using random forest analysis [29] based on the proportion of IFNc-expressing CD4 + , CD45RO + T cells against 13 selected stimuli (i.e. PPD, ESAT6_CFP10, Rv0569, Rv1733c, Rv1734, Rv2003, Rv2005c, Rv2006, Rv0140, Rv1009, Rv1884c, Rv2450c, and Rv3407). We determined the relative feature importance for discrimination using a leave-1-out cross validation for all possible combinations of genes and assessed the proportion of correctly classified patients in the left-out group.
For significance analyses the Mann-Whitney U-test was used. Significance of two-sided p-values is indicated as follows: * P,0.05, ** P,0.01, and *** P,0.001.
